Growth Hormone - Responsive Dermatosis (Adult-Onset Hyposomatotropism, Pseudo-Cushing's Syndrome)
- Possible deficiency in growth hormone that develops after maturity
- Atrophy of pituitary gland in one case
- Adrenal sex hormone abnormality
- Breed Predilection - Chow Chows, Keeshond, Pomeranian, Miniature Poodle
- Age Predilection - 1-3 years old
- Sex Predilection - intact male dogs
- Bilaterally symmetrical alopecia and hyperpigmentation - primarily neck, perineal and genital regions, tail, posterior and medial thighs, ventral abdomen
- Excess scaling and dull, dry hair coat
- Changes in hair coat color
- Regrowth of hair in areas of full thickness trauma to the skin
- Appears clinically similar to castration responsive dermatosis
- Skin biopsy - consistent with endocrinopathy, presence of eosinophilic tricholemmal keratinization ("flame follicles").
- Growth hormone stimulation test - see pituitary dwarfism. Low or normal baseline growth hormone levels with a poor response to stimulation (xylazine) can be normal for Pomeranians.
- Must differentiate from castration responsive dermatosis - (measure serum estradiol, progesterone, and testosterone) and adrenal sex hormone dermatosis.
- Growth Hormone treatment (bovine) - 2.5 units (less than 14 kg) - 5.0 units (greater than 14 kg) SQ every other day for 10 injections.
- Should see response within 3 months
- Effective for 6 months to 3 years
- Many cases have not responded completely
- May induce diabetes mellitus, acromegaly
- Hormone is very difficult to obtain
- Human Growth Hormone - 0.15 IU/kg SQ twice weekly for six weeks
Castration Responsive Dermatosis
- Etiology - A mild to moderate elevation of serum estradiol in intact male dogs
- Histologically normal testicles with normal descent of testicles
- Sex Predisposition - intact male dogs
- Breed Predisposition - Pomeranian, Chow Chow, Miniature Poodle, Keeshond
- Bilaterally symmetrical alopecia and hyperpigmentation - affects the neck, perineal and genital region, tail, posterior and medial thighs, ventral abdomen
- Excess scaling and dull, dry hair coat, Fuzzy hair coat, Changes in hair coat color, Regrowth of hair in areas of full thickness trauma to skin
- History of normal descent of testicles that palpate normal on physical examination
- History and physical examination
- Mild to moderate elevations in estradiol
- Also measure progesterone and testosterone
- GnRH response test - 0.1 ug/lb GnRH (Cystorelin) IV, take baseline + 1 and 2 hour post-GnRH samples
- May have multiple endocrine abnormalities revealed on TSH response test, cortisol function test, growth hormone stimulation tests
- Consistent with an endocrinopathy, Brightly eosinophilic tricholemmal keratinization ("flame follicles")
- Testicular biopsy – normal
- Castration - response in 2-3 months
Adrenal Sex Hormone Dermatosis
- Defect in adrenal steroidogenesis, A partial 21-hydroxylase enzyme deficiency proposed, Results in increased serum progesterone, 17-hydroxyprogesterone, dehydroepiandrosterone (DHEAS), androstenodione, Elevated basal plasma ACTH
- Sex Predisposition - intact male and female dogs
- Breed Predisposition - Pomeranians, Chow Chows, Keeshonds, Samoyeds
- Bilaterally symmetrical alopecia and hyperpigmentation - affects the neck, perineal and genital region, tail, posterior and medial thighs, ventral abdomen
- Excess scaling and dull, dry hair coat, Fuzzy hair coat, Changes in hair coat color, Regrowth of hair in areas of full thickness trauma to the skin
- Appears clinically similar to Growth Hormone - Responsive Dermatosis and Castration Responsive Dermatosis
- History and physical exam
- ACTH stimulation test - Reproductive hormone panel
- Baseline EDTA and clot tube samples
- Give 0.5 IU/kg ACTH (Cosyntropin) IV
- Collect 1 hour post-ACTH samples
- Samples measured for cortisol, 11-deoxycortisol, DHEAS, androstenedione, 17-hydroxyprogesterone, progesterone, testosterone, and estradiol
- Growth hormone stimulation test - may have concurrent poor responsiveness to xylazine stimulation
- Skin biopsy - consistent with and endocrinopathy, presence of eosinophilic tricholemmal keratinization ("flame follicles")
- o.p'-DDD (Lysodren) - 15-25 mg/kg, SID for 5 days, then q 7-14 days as maintenance
- Monitor cortisol function with ACTH response test
- Ketoconazole (Nizoral) - 30 mg/kg, divided BID-TID
- Decreases cholesterol synthesis, decreases serum basal cortisol and testosterone, Increases serum basal progesterone and 17-hydroxyprogesterone
- Methyltestosterone - 0.5 mg/lb q 48 h (maximum dose of 30 mg/dog) x 30-60 days, then 1-2x weekly.
- Melatonin – 3-6 mg/dog TID
- Trilostane – 5-10 mg/kg/day
Alopecia X – Latest Theories
- Follicular growth dysfunction of plush-coated breeds
- Primary hair follicle receptor defect
- Abnormal receptor response to a normal hormone signal - Similar to male pattern baldness
- Genetically determined disease
- Multi-genetic trait, Pomeranians as the prototype
- May be similar in the Chow Chow, Keeshond, Samoyeds, Siberian Husky, Alaskan Malamute
- Selective breeding for the trait neotony - Retention of the juvenile prototype, Retention of the “puppy coat” (plush coat)
- Mild but prolonged increase in basal cortisol
- Normal ACTH response tests, Increased urinary cortisol/creatinine ratio, Slightly enlarged adrenals on abdominal ultrasound
Alopecia X – Treatment Approach
- Castration or OHE - Treatment of choice if intact
- Alters sex hormone levels, Increase in growth hormone factors
- Lethargy, insulin resistance
- Benign neglect - only an aesthetic disease – “Buy the dog a sweater”
- 1 mg/kg q48h (max dose of 30 mg/dog) x 30-60 days, then 1-2 x weekly
- Finasteride (Propecia®, Proscar®)
- 5 alpha-reductase inhibitor, Block DHT production
- Leuprolid acetate (Lupron®)
- Causes decreased endogenous GnRH production, decreased FSH and LH, decreased sex hormones
- Panting, anxiety – “hot flashes”
- Topical Cyproterone –blocks DHT receptors
- 15-25 mg/kg – SID x 5 days, then q 7-14 days as maintenance
- Hypoadrenocorticism potential
- Trilostane (Vetoryl®, Modrenal®)
- Dogs with cardiac disease at risk
- Hypoadrenocorticism potential
- Gradually increase dosage
- Metoclopramide (Reglan®) – 0.2-0.5 mg/kg TID
- Maropitant citrate (Cerenia®) – 2 mg/kg SID, 1 hour prior to cyclosporine x 4 days.
- Psoriasiform-Lichenoid drug eruption, Gingival hyperplasia, Hypertrichosis
- Increased risk of neoplasia – lymphosarcoma??
- Based on observation of re-growth of hair at sites of full thickness skin trauma (skin biopsies and incision sites)
- Use of a dish washing “Scotch Pad”